- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03929120
Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
April 6, 2023 updated by: Andy Abril, M.D., Mayo Clinic
A Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients With Connective Tissue Disorders
Researchers are trying to find out more about the safety of a new treatment, Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) which is still experimental, for Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic in Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults over 18 years of age and less than 80 years of age
- Both female and male
- Patients with new diagnosis of interstitial lung disease associated with connective tissue disorders, Antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis or idiopathic pneumonia with autoimmune features (IPAF) or established diagnosis of ILD associated with CTD under conventional therapy for at least 6 months but less than 24 months, with no evidence of improvement.
- Competent and able to provide written informed consent, and ability to comply with protocol
Exclusion Criteria:
- Patients with interstitial lung disease without evidence of a concomitant rheumatologic autoimmune disorder
- Exposure to rituximab or cyclophosphamide on the previous 2 months
- Severe interstitial lung disease defined by the presence of severe hypoxemia at rest (SO2 < 88% at rest)
- Clinical assessment that indicates active chronic infections such as osteomyelitis or active tuberculosis (TB), or acute infections such as pneumonia, active bronchitis, cellulitis, etc. or active solid tumors or hematologic malignancies
- Previous treatment with mesenchymal stem cells
- Clinically significant medical conditions within the six months before administration of BMD-MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient.
- Medical history of human immunodeficiency virus (HIV), Hepatitis B or C
- Abnormal complete blood count (CBC), creatinine, Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) at screening
- Pregnant or breast feeding
- Unwilling to agree to use acceptable contraception methods during participation in the trial
- Inability to provide informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interstitial Lung Disease with Connective Tissue Disorder
Subjects with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD) will receive a new treatment called Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
|
Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 6 months
|
Number of adverse events reported with infusion of each intravenous Mesenchymal Stem Cells (MSC) dose
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Andy Abril, MD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 5, 2019
Primary Completion (Actual)
July 27, 2021
Study Completion (Actual)
February 2, 2022
Study Registration Dates
First Submitted
April 24, 2019
First Submitted That Met QC Criteria
April 24, 2019
First Posted (Actual)
April 26, 2019
Study Record Updates
Last Update Posted (Actual)
April 7, 2023
Last Update Submitted That Met QC Criteria
April 6, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-007216
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Connective Tissue Diseases
-
Hospital for Special Surgery, New YorkRecruitingUndifferentiated Connective Tissue DiseaseUnited States
-
The University of Hong KongCompleted
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Poitiers University HospitalTerminated
-
AbbottCompleted
-
Sunnybrook Health Sciences CentreSunnybrook Research Institute; Arrayus Technologies Inc.Active, not recruiting
-
Trieu, Nguyen Thi, M.D.Completed
Clinical Trials on Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
-
The Cleveland ClinicCase Western Reserve UniversityWithdrawnInflammatory Bowel Diseases | Crohn's Disease | Pouchitis | Ulcerative Colitis Chronic | Pouch, IlealUnited States
-
The Cleveland ClinicWithdrawnFistula | Crohn's Disease | Anal Fistula | Pouch, Ileal | Pouches, Ileoanal
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos III; Universidad Carlos III Madrid (TERMeG); St John... and other collaboratorsUnknownEpidermolysis Bullosa Dystrophica, RecessiveSpain
-
National University of MalaysiaCytopeutics Sdn. Bhd.UnknownIschemic Dilated CardiomyopathyMalaysia
-
The University of Texas Health Science Center,...RecruitingTreatment-resistant Bipolar DepressionUnited States
-
Michael A. MatthayMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedAcute Respiratory Distress SyndromeUnited States
-
Clinica Santa Clarita, MexicoWithdrawnKnee OsteoarthritisMexico
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR); Stem Cell Network; Ontario Institute...UnknownPathologic Processes | Sepsis | Systemic Inflammatory Response Syndrome | Inflammation | Shock | Septic Shock | Infection
-
Indiana UniversityActive, not recruitingIschemia | Pathologic Processes | Arteriosclerosis | Cardiovascular Disease | Peripheral Arterial Disease | Atherosclerosis | Amputation | Peripheral Vascular Disease | Orthopedic Procedures | Vascular Disease | Arterial Occlusive DiseaseUnited States
-
Uppsala UniversityUppsala University HospitalActive, not recruitingCOVID | ARDS, HumanSweden